ZOL pre-treatment of the hepatoma cell lines was again required in order to evoke substantial IFN-γ and TNF-α expression by the expanded blood Vγ9Vδ2 TRM (Fig. 7e, Supplementary Fig. 7h), which was reduced in a dose-dependent manner by the addition of Mevastatin, confirming the dependence on tumour cell IPP expression (Fig. 7f, Supplementary Fig. 7i). This evidence concerns the gene IFNG and hepatocellular carcinoma.